Reviewer's report

Title: Rationale and design of LUX-Head & Neck 2: A randomised, double-blind, placebo-controlled, phase III trial of afatinib as an adjuvant therapy after chemoradiation in primary unresected, clinically intermediate- to high-risk head and neck cancer

Version: 2 Date: 28 August 2014

Reviewer: Mehmet Sen

Reviewer's report:

Discretionary Revisions
Author`s response to previous reviews has been noted. 7 July 2014

Trials Status section (page 15) . Name of the participating countries added.
It would be useful to provide current recruitment numbers to date.

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:
I received a fee as advisory board member to Boehringer Ingelheim PharmaceuticalsI during the last 5 years. This will not cause any gain or lose financially from the publication of this manuscript.

The remaining items mentioned above otherwise I declare that I have no competing interests